SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors aggressively price in the company's expanding AI infrastructure footprint and recent strategic acquisitions, with community sentiment driven by a potential short squeeze and anticipation of upcoming earnings. Enthusiastic discussions are centered on the company's competitive positioning as a 'fourth hyperscaler' and its ability to secure major multi-billion dollar contracts, leading to significant momentum that has pushed the stock to new highs.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors scrutinize potential Matrix-M partnership developments following an earnings beat, while the community remains sharply divided over governance and the push for leadership changes via upcoming proxy votes. Discussions are heavily focused on the company's licensing platform strategy versus lingering concerns about cash burn and the lack of specific deal disclosures.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing significant investor attention driven by strong Q1 earnings, which highlighted 55% revenue growth and improved margins as the company transitions into a pure-play edge AI and defense-focused business. The community is actively discussing the stock's potential for rerating alongside the broader push for ruggedized, mission-critical AI infrastructure within defense and industrial sectors.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is experiencing a massive parabolic rally fueled by intense AI-driven demand for memory chips, with the stock recently hitting all-time highs above $1,400. While bulls are celebrating massive gains and pointing to long-term storage shortages, the community is actively debating whether this movement reflects genuine AI-fueled fundamental growth or an unsustainable speculative bubble.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors rally behind the company's global expansion efforts and a massive short interest, which many believe is primed for a potential squeeze. The community is actively tracking Dr. Patrick Soon-Shiong's recent communications, viewing the company's international reach and AI-driven manufacturing as catalysts for future value despite ongoing regulatory volatility.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is currently at the center of investor focus following a massive 15-year, $9.8 billion AI data center lease, which has sparked a strong rerating narrative as the company shifts from a crypto miner to an AI infrastructure leader. While some community members remain skeptical of the transition and the reliance on major hyperscalers, bulls are aggressively highlighting the stock's long-term potential, leading to intense debates over its valuation and recent parabolic price action.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc

Ernexa Therapeutics is seeing heightened activity driven by a new manufacturing collaboration with Cellipont Bioservices intended to advance their ovarian cancer candidate, ERNA-101, into clinical trials. While some investors are optimistic about the potential for a squeeze due to the company's low float and strong institutional presence, others are expressing significant caution regarding the stock's history of dilution and reverse splits.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is trending as investors react to a pivotal transition toward AI infrastructure and high-performance computing, bolstered by a significant data center revenue beat and a partnership expansion with AMD. While some traders are expressing frustration over historical volatility and recent executive changes, the community remains actively focused on the stock's potential for a broader re-rating as it pivots to a vertically integrated energy and AI compute model.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently experiencing significant volatility as investors debate the potential synergy of its Disney partnership and its upcoming earnings report. The community remains deeply divided between bulls anticipating a short squeeze or profitable turnaround and bears citing ongoing subscriber losses and management's past performance as reasons for further downside.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing strong bullish momentum as investors react to positive commercial execution for Briumvi and optimism surrounding upcoming clinical trial readouts. The community is actively discussing the potential for a strategic buyout given the stock's role in the highly competitive multiple sclerosis market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at the Bank of America Securities Healthcare Conference 2026 on Thursday, May 14, 2026. The company will take part in a...

Bokf Na Reduces Stock Position in Bristol Myers Squibb Company $BMY

Bokf Na lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 10.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange...

Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth

Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know  

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Bristol Myers Squibb Company $BMY Shares Sold by RNC Capital Management LLC

RNC Capital Management LLC decreased its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 7.0% in the 4th quarter, according to its most recent filing with the Securities and...

Bristol Myers Squibb Company $BMY Shares Bought by Intact Investment Management Inc.

Intact Investment Management Inc. raised its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 88.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 106,100 shares of the biopharmaceutical company's stock after acquiring...

Varma Mutual Pension Insurance Co Boosts Stock Holdings in Bristol Myers Squibb Company $BMY

Varma Mutual Pension Insurance Co raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 15.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 353,026 shares of the biopharmac...

Seizert Capital Partners LLC Acquires 38,725 Shares of Bristol Myers Squibb Company $BMY

Seizert Capital Partners LLC lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F...

Bristol Myers Squibb Launches Won't Lose Media Campaign Ahead of FIFA World Cup 2026

Bristol Myers Squibb (NYSE: BMY) today announced the launch of Wont Lose, a new campaign debuting ahead of the FIFA World Cup 2026. Leveraging a major cultural and global moment, the Wont Lose...

Mcdonald Partners LLC Grows Holdings in Bristol Myers Squibb Company $BMY

Mcdonald Partners LLC raised its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 284.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,229 shares of the biopharm...

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$1.61	--	--	N/A
Q1 '26	$1.42	$1.58	10.99%	BEAT
Q4 '25	$1.23	$1.26	2.79%	BEAT
Q3 '25	$1.51	$1.63	8.00%	BEAT
Q2 '25	$1.07	$1.46	36.87%	BEAT

BMY
Bristol-Myers Squibb Co.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest BMY News

BMYBristol-Myers Squibb Co.